The best time to take dasatinib

Dasatinib (Dasatinib) is an oral drug used to treat chronic myelogenous leukemia (CML) and some treatment-resistant chronic myelogenous leukemia. It belongs to a class of drugs called tyrosine kinase inhibitors, which slow the proliferation and growth of leukemia cells by inhibiting the activity of abnormally active tyrosine kinase enzymes.

As a targeted therapy drug, dasatinib has high selectivity and mainly acts on the BCR-ABL gene fusion protein, which is the main causative gene of chronic myelogenous leukemia. By blocking the activity of this protein, dasatinib can reduce the number of abnormally proliferating leukemia cells and thereby control the progression of the disease.

The dosage regimen of dasatinib is usually formulated by a doctor based on the patient's specific condition and severity of illness. Chronic phase of chronic myeloid leukemia: 100 mg orally, once a day; Accelerated phase of chronic myeloid leukemia, myeloid or lymphoblastic leukemia, Ph+ ALL: 140 mg, orally, once a day.

Although dasatinib (Startax) is generally considered a relatively safe drug, there are still some potential side effects, including nausea, vomiting, diarrhea, fatigue, headache, etc. In addition, long-term use may also lead to some more serious side effects, such as bleeding tendencies, heart problems, abnormal liver function, etc. Therefore, patients need to closely monitor their physical condition and undergo regular examinations while taking Dasatinib.

Overall, Dasatinib (Startase) is a very effective drug in the treatment of chronic myelogenous leukemia, helping to control the progression of the disease and improve patient survival rates. However, patients need to monitor closely and follow their doctor's recommendations during use to minimize potential side effects and risks.